Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/IIa clinical proof-of-concept trial of RTX-134 for the treatment of phenylketonuria

Trial Profile

A Phase I/IIa clinical proof-of-concept trial of RTX-134 for the treatment of phenylketonuria

Planning
Phase of Trial: Phase I/II

Latest Information Update: 07 Jan 2019

At a glance

  • Drugs RTX-134 (Primary)
  • Indications Phenylketonuria
  • Focus Adverse reactions; Proof of concept
  • Sponsors Rubius Therapeutics
  • Most Recent Events

    • 07 Jan 2019 According to a Rubius Therapeutics media release, initial clinical data from part1 of this study is expected in the second half of 2019.
    • 14 Sep 2018 New trial record
    • 31 Aug 2018 According to a Rubius Therapeutics media release, the company intends to file an IND application for RTX-134 for Phenylketonuria in the first quarter of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top